Indianapolis , IN 46202
I am a geriatrician, a neuroscientist, and implementation scientist with a goal of using insights from behavioral economics, complexity science, and network science to develop, implement and distribute an innovative, sustainable and scalable “Blue Print” of the 21st Century learning Academic healthcare delivery system. Such an agile social organization will be able to reduce the 17-year cycle of developing and translating innovative, cost effective, and scalable medical innovations. At the same time, the learning system will be capable of delivering personalized, evidence-based, and valued healthcare with a great experience for clinicians, learners, and patients.
I have built a Clinical Aging Brain Care Learning Laboratory across two health care systems in Indiana; Indiana University Health, a statewide system that include 17 hospitals; and Eskenazi Health, a safety net health system serving the need of the underprivileged Marion County residents in Indianapolis. Through this Clinical Laboratory I have led numerous observational and clinical trials studies totaling more than $70 million of funding from the NIH, AHRQ, and CMS. Below are examples of research programs that I am directing. I was the PI of NIA funded cross-sectional study that investigated the attitudes of more than 1,000 older primary care patients and their family members toward dementia screening (R01AG029884); I completed the first randomized controlled trial investigating the benefits and harms of dementia screening among 4,000 older adults attending rural and urban primary care clinics in central Indiana (R01AG040220); I developed and disseminated a scalable version of the collaborative care model for dementia and depression, known as the Indian University Aging Brain Care Model, across the state of Indiana (1C1CMS331000-01-00); I just completed two randomized controlled clinical trials that investigated the efficacy of pharmacological management protocols in reducing the severity and the duration of delirium among 500 critically ill hospitalized patients (R01AG034205; R24MH080827); I published the results of the first randomized clinical trial investigating the medication adherence and safety of the three currently available cholinesterase inhibitors for the treatment of Alzheimer Disease (R01HS019818); I just completed a study funded by Merck Pharmaceutical to use machine learning to develop a scalable passive digital markers of early Alzheimer disease and other dementing illness(ADRD); and just recently, my team received funding from the NIH for conducting two clinical trials in evaluating the impact of De-prescribing anticholinergic medications in preventing ADRD.
Titles & Appointments
- Richard M. Fairbanks Professor of Aging Research
- Professor of Medicine
- Adjunct Professor of Surgery
- Founding Director and Implementation Scientist, Center for Health Innovation &
- Implementation Science
- Founding Director, Chief Innovation and Implementation Officer, Sandra Eskenazi Center for Brain Care Innovation
- Research Scientist, Indiana University Center for Aging Research
- Director, Senior Care Innovation, Eskenazi Health